You are here
U.S. Pays More Than Twice the Price Charged in Europe for Cancer Meds
An analysis suggesting that pharmaceutical companies are charging up to 600 times what the medicines cost will be presented at the European Cancer Congress in Vienna from September 25 to 29. This independent academic study conducted by pharmacologist Andrew Hill of Britain's University of Liverpool is likely to fuel a growing storm over U.S. drug costs.
The United States pays more than double the price charged in Europe for these so-called tyrosine kinase inhibitors (TKIs), a potent class of cancer pills with fewer side effects than chemotherapy.
Hill told Reuters he had shared his work on the cost of producing TKIs with the World Health Organization (WHO), which is keen to add such treatments to its list of medicines deemed essential for a basic health care system. WHO officials have used the findings in determining that the drugs can be made at low cost, he said. The first TKI was added to the WHO's latest draft Essential Medicines List earlier this year.
Several widely-used TKIs are expected to become available as generics within the next five years as patents expire. Hill calculated that large-scale production could achieve treatment prices in the range of $159 to $4,022 per person a year, compared with current U.S. prices of around $75,000 to more than $100,000.
"It shows there is a lot of scope for prices to come down," he said. "There has to be some middle ground between the prices that companies are charging, which may not even be cost-effective by the standards set by some health care authorities, and the actual production cost."
Drug companies argue that they need to make decent profits to pay for the billions of dollars needed for drug research. Many companies also have extensive low-cost or even free access schemes for patients who cannot afford their medicines. But the high prices charged for modern drugs are generating increasing push-back from health care providers, patients, and some doctors.
Hill used Indian government data on the cost of pharmaceutical ingredients and allowed for a 50% profit margin — but no money for investment in research — to work out the costs of producing certain drugs.
On this basis, he found that Novartis' leukemia drug Glivec actually cost $159 for a year's treatment, against the $106,000 charged in the United States, where it is branded as Gleevec. Roche's Tarceva for lung cancer cost $236, against a U.S. price of $79,000, and Novartis' Tykerb cost $4,000 against a price of $74,000.
In all these cases the U.S. cost was far above that charged in certain western European countries, where Glivec costs approximately $29,000 to $35,000, Tarceva $26,000 to $29,000, and Tykerb around $35,000, Hill reported.
Novartis said the price of medicines is determined by many factors beyond manufacturing costs, including their value to patients and health care systems. "We invest in developing novel and current treatments to find ways to make more cancers survivable. This is challenging and risky and needs to be taken into consideration when discussing pricing of treatments," a spokeswoman said.
Roche declined to comment.
The issue is not unique to cancer drugs. Earlier this month, for example, Amgen launched its new injectable cholesterol drug Repatha in Europe at around half the U.S. price.
"Why should the U.S. bear this huge burden cost? It is not as if the GDP of the United States is so much higher than that of European countries, but they just seem to pay these big premiums," Hill said.
The future pricing of TKIs could also have major implications for developing countries, Hill believes, since mass production could open the way to widespread cancer treatment in the same way that cheap generic drugs helped fight HIV/AIDS.
Source: Reuters; September 22, 2015.